Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,030.00
+85.00 (2.15%)
At close: Aug 24, 2026

Jin Yang Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
124,611120,686113,33293,70876,26462,839
Revenue Growth
4.12%6.49%20.94%22.87%21.36%26.88%
Gross Profit
82,25778,15169,88457,05645,65133,984
Operating Income
3,7902,52611,7088,68211,1386,964
Net Income
22,80422,28729,69412,34012,3089,538
Earnings Per Share
-1789.412408.01988.98915.61835.60
EPS Growth
--25.69%143.48%8.01%9.57%78.63%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
7,2915,8882,0138,59510,49414,875
Total Debt
76,04076,75779,6827,83119,98220,013
Net Cash (Debt)
-68,750-70,869-77,668764.1-9,488-5,138
Net Cash Growth
------
Net Cash Per Share
--5690.03-6298.4061.24-705.79-450.13

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
10,7531,46512,7928,5347,4481,971
Capital Expenditures
-7,914-4,266-90,060-682.28-3,218-2,516
Free Cash Flow
2,838-2,801-77,2687,8514,230-545.86
Free Cash Flow Growth
---85.62%--

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
66.01%64.76%61.66%60.89%59.86%54.08%
Operating Margin
3.04%2.09%10.33%9.26%14.61%11.08%
Pretax Margin
23.36%23.28%32.69%13.00%19.06%19.31%
Profit Margin
18.30%18.47%26.20%13.17%16.14%15.18%
FCF Margin
2.28%-2.32%-68.18%8.38%5.55%-0.87%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
2.232.912.245.415.718.25
P/FCF Ratio
17.94--8.5116.61-
PS Ratio
0.410.540.590.710.921.25